TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7032226
Drug: Divided doses
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided doses of chlorpromazine (100 mg, thrice daily)
Study: 23958332
Drug: Brief Social
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Social Behavior and Network Therapy (B‐SBNT)
Study: 23958332
Drug: B‐SBNT and
Approvals — FDA: no, EMA: no, PMDA: no
Description: B‐SBNT and PGS (plus routine treatment)
Study: 18289903
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (GH) starting dose of 0.1mg/day, adjusted to maintain IGF‐I levels between 0 and 2 SDS for gender and age.
Study: 18289903
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GH therapy)
Study: 14693710
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in 2-h postglucose insulin levels
Study: 2390518
Drug: Oral fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluorescein (25 mg/kg body weight)
Study: 2390518
Drug: Oral fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluorescein (capsules)
Study: 2390518
Drug: Intravenous fluorescein
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fluorescein
Study: 22233415
Drug: Thymosin alpha-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha-1 1.6 mg SC twice weekly for 48 weeks
Study: 22233415
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (peginterferon alfa-2a 180 mg/week with RBV 800-1200 mg/daily)
Study: 17570054
Drug: Behaviorally-modified dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviorally-modified dental intervention (splint therapy) using an interocclusal appliance worn up to 20 hours per day for 4 weeks.
Study: 16262733
Drug: Daily self-administered
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-administered 6-month regimen of rifampicin and isoniazid
Study: 16262733
Drug: Twice-weekly, directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly, directly observed 6-month regimen of rifampicin and isoniazid plus pyrazinamide for the first 2 months
Study: 10440436
Drug: Ampicillin/sulbactam (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (150 to 300 mg/kg/day in divided doses every 6 hours)
Study: 10440436
Drug: Cefuroxime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (50 to 100 mg/kg/day in divided doses every 6 or 8 hours)
Study: 7758054
Drug: NIF CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIF CC 30 mg daily with food
Study: 7758054
Drug: NIF GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIF GITS 30 mg daily with food
Study: 7758054
Drug: NIF CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIF CC
Study: 28905108
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg/day, days 1-21)
Study: 28905108
Drug: S-1 (80-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80-120 mg/day, days 1-14)
Study: 26738328
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Tamsulosin at 0.2 mg qd plus Xipayimaizipizi at 0.5 g tid)
Study: 26738328
Drug: Control (Tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Tamsulosin at 0.2 mg qd)
Study: 20964867
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral ibandronate (150 mg)
Study: 15203552
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg every other day orally
Study: 11593074
Drug: Fluvoxamine, Clomipramine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine, Clomipramine, Citalopram, Paroxetine (standardized treatment over 12 weeks)
Study: 25671925
Drug: Intravenous Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Morphine 0.1mg/kg and Intravenous lidocaine 1.5 mg/kg
Study: 25671925
Drug: Intravenous Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Morphine 0.1mg/kg and lidocaine spray 1.5 mg/kg
Study: 24231018
Drug: Higher-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-protein diet (HP: 32% protein; 12.2 mg/day iron; 11.7 mg/day zinc)
Study: 24231018
Drug: Lower-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-protein diet (LP: 20%; 9.9 mg/day iron; 7.6 mg/day zinc) with >=10% weight loss
Study: 20121898
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 g three times daily)
Study: 20121898
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g three times daily)
Study: 19216279
Drug: Implant-supported removable
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported removable partial denture (ISRPD)
Study: 12668989
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution (75 g)
Study: 10376778
Drug: Pistachio nuts
Normalized name: Pistachio nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio nuts (20% of daily caloric intake)
Study: 6370438
Drug: 0.05% diflorasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% diflorasone diacetate ointment in a vehicle of propylene glycol (PG)
Study: 19784470
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate ointment
Study: 29929610
Drug: Double volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double volume saline (2 ml/kg/h for 12 h before and after the procedure)
Study: 29929610
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume saline (1 ml/kg/h for 12 h before and after the procedure)
Study: 24528614
Drug: Oral rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rapamycin plus bare-metal stent (OR)
Study: 20232758
Drug: Oral simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral simvastatin (40 mg/d) plus topical betamethasone (50% in petrolatum) for 8 weeks
Study: 20232758
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo plus topical betamethasone (50% in petrolatum) for 8 weeks
Study: 15050090
Drug: Family cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family cognitive‐behavioral therapy
Study: 15050090
Drug: Individual cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive‐behavioral therapy
Study: 9734756
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation 1.5 mg/kg for 15 days
Study: 9734756
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation 6.0 mg/kg for 15 days
Study: 9734756
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation 6.0 mg/kg for 30 days
Study: 7520659
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) treatment
Study: 4919024
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg twice a day
Study: 17509689
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib sodium (1 mg or 3 mg) every 6 weeks for 54 weeks
Study: 15632883
Drug: Coumadin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coumadin plus aspirin
Study: 28600024
Drug: Cilostazol plus
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol plus aspirin
Study: 9820393
Drug: Self-reported rectal
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported rectal bleeding
Study: 9820393
Drug: Self-reported rectal
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported rectal bleeding (blood on wiping)
Study: 9820393
Drug: Self-reported rectal
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported rectal bleeding (blood coating stools)
Study: 9820393
Drug: Self-reported rectal
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported rectal bleeding (dark blood mixed in stools)
Study: 8575676
Drug: Gyno-Pevaryl 150
Normalized name: econazole nitrate Topical Powder [Pevaryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gyno-Pevaryl 150 treatment
Study: 8575676
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without G-P 150 treatment)
Study: 2234646
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin therapy
Study: 2234646
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy or research in pregnancy
Study: 685753
Drug: Aspirin, 1200
Normalized name: Aspirin, 1200 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 1200 mg/day
Study: 685753
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Sulfinpyrazone
Study: 28245383
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (hydroxyurea plus IFN‐α)
Study: 28245383
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment group (hydroxyurea)
Study: 22985776
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy plus chemotherapy (IMRT-C)
Study: 17672073
Drug: Nimesil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesil (200 mg/day)
Study: 17672073
Drug: Aponil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aponil (200 mg/day)
Study: 17672073
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac (150 mg/day)
Study: 343226
Drug: Plain acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain acetylsalicylic acid (ASA) tablet
Study: 343226
Drug: Microencapsulated acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microencapsulated acetylsalicylic acid (ASA) tablet
Study: 343226
Drug: Control examinations
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control examinations (before ASA treatment)
Study: 28605879
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (Enoxaparin) alone
Study: 28605879
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (Enoxaparin followed by Rivaroxaban)
Study: 23470649
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 2 g/kg total dose (400 mg/kg per day for 5 days)
Study: 23470649
Drug: Anti-D immunoglobulin
Normalized name: Anti-D immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-D immunoglobulin 50 μg/kg
Study: 23470649
Drug: Anti-D immunoglobulin
Normalized name: Anti-D immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-D immunoglobulin 75 μg/kg
Study: 10211920
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily plus pindolol 7.5 mg daily
Study: 10211920
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily plus mianserin 30 mg daily
Study: 1860197
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg preoperatively
Study: 7046498
Drug: Etomidate (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.1 mg/kg) preceded by diazepam (0.1 mg/kg)
Study: 20463100
Drug: Calcium (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1200 mg daily) plus placebo
Study: 24064695
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (100 μg) plus placebo
Study: 12767658
Drug: Juice Plus
Normalized name: Nutritional Supplement Oral Liquid [JUICE PLUS WITH FIBER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice Plus (JP) and Vineyard (V) combination
Study: 12767658
Drug: Juice Plus
Normalized name: Nutritional Supplement Oral Liquid [JUICE PLUS WITH FIBER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice Plus (JP) and Vineyard (V) combination and JP alone
Study: 10694785
Drug: High flavonols
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavonols diet (77.3 mg/day or 110.4 mg/day)
Study: 8218961
Drug: Celaskon 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celaskon 60 mg (CK60)
Study: 8218961
Drug: Celaskon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celaskon 500 mg (CK500)
Study: 28903787
Drug: Metacognitive methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive methods combined with habit reversal therapy (MCT/HRT)
Study: 15816634
Drug: Complementary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complementary administration of standardized mistletoe extract (Iscador)
Study: 14676074
Drug: Rofecoxib (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (up to 37.5 mg)
Study: 14676074
Drug: Celecoxib (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (up to 300 mg)
Study: 14676074
Drug: Aspirin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (up to 500 mg)
Study: 14676074
Drug: Aspirin-induced urticaria
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin-induced urticaria
Study: 1863024
Drug: pH‐sensitive, polymer‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH‐sensitive, polymer‐coated oral preparation of mesalamine 2.4 g/d
Study: 1863024
Drug: pH‐sensitive, polymer‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH‐sensitive, polymer‐coated oral preparation of mesalamine 1.6 g/d
Study: 25259747
Drug: Bedtime administration
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime administration of antihypertensive drugs
Study: 22959763
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone
Study: 19665364
Drug: Ephedrine 6
Normalized name: pseudoephedrine 6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 6 mg (group E)
Study: 16079222
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (3 kcal/min) with guar gum (4 g)
Study: 24525810
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg daily)
Study: 1321037
Drug: Propofol (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (LD 2 mg kg‐1 and MD 6 mg kg‐1 h‐1)
Study: 1321037
Drug: Etomidate (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (LD 0.3 mg kg‐1 and MD 0.6 mg kg‐1 h‐1)
Study: 1321037
Drug: Midazolam (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (LD 0.2 mg kg‐1 and MD 0.120 mg kg‐1 h‐1)
Study: 1321037
Drug: Methohexitone (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone (LD 1.5 mg kg‐1 and MD 4 mg kg‐1 h‐1)
Study: 1321037
Drug: Dehydrobenzperidol (0.05-0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydrobenzperidol (0.05-0.23 mg kg‐1) and alfentanil (LD 0.100 mg kg‐1 and MD 0.060 mg kg‐1 h‐1)
Study: 6547878
Drug: pindolol, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol, 15 mg daily
Study: 6547878
Drug: hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide, 50 mg daily
Study: 6547878
Drug: both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: both drugs combined
Study: 25354407
Drug: Podiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Podiatric treatment
Study: 18991037
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% monotherapy for 12 weeks
Study: 18991037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Latanoprost 0.005% and Nipradilol 0.25% after 12 weeks
Study: 18991037
Drug: Nipradilol 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipradilol 0.25% monotherapy for 12 weeks
Study: 18991037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nipradilol 0.25% and Latanoprost 0.005% after 12 weeks
Study: 12017304
Drug: Post-operative adjuvant
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative adjuvant chemotherapy including mitomycin, anthracyclines, cyclophosphamide, alkylating agents, and 5-fluorouracil
Study: 12017304
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with mitomycin, 5-fluorouracil and non-specific immunomodulators (PSK and OK-432)
Study: 12017304
Drug: Post-operative adjuvant
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative adjuvant chemotherapy or immunochemotherapy
Study: 9718288
Drug: Cotinine fumarate
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotinine fumarate 40 mg
Study: 9718288
Drug: Cotinine fumarate
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotinine fumarate 80 mg
Study: 9718288
Drug: Cotinine fumarate
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotinine fumarate 160 mg
Study: 7917540
Drug: vindesine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: vindesine (3 mg/m2/week) plus interferon-alpha 2b (6 U/m2 3 times per week)
Study: 2523921
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of cromoglycate (C)
Study: 3902672
Drug: Timolol 10
Normalized name: timolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 10 mg twice daily
Study: 7034470
Drug: Timolol 5
Normalized name: timolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 5 mg
Study: 20009091
Drug: Monthly care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly care coordination telephone call (CC group)
Study: 16037156
Drug: Ganoderma lucidum
Normalized name: GANODERMA LUCIDUM STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganoderma lucidum capsules 1.5 g daily for 4 weeks
Study: 10687910
Drug: 1‐mg increments
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐mg increments of midazolam at 1‐min intervals
Study: 10687910
Drug: 0.1‐mg increments
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1‐mg increments of midazolam without a lock‐out interval
Study: 1725892
Drug: Oral nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicardipine (3 x 30 mg)
Study: 31610637
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg body weight via 12 ounces of coffee)
Study: 27618781
Drug: Percutaneous radiofrequency
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous radiofrequency coagulation of the facet joint capsule
Study: 20591628
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 1000 mg/day for 14 weeks
Study: 17266067
Drug: Mindfulness-Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Stress Reduction (MBSR), 8-week intervention, 2.5-hour sessions weekly, led by a licensed clinical psychologist.
Study: 12764515
Drug: Praziquantel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (60 mg/kg per day for three consecutive days)
Study: 12764515
Drug: Oxamniquine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine (two daily doses of 10 mg/kg)
Study: 10600424
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of ascorbic acid supplementation per day
Study: 10600424
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of ascorbic acid supplementation per day
Study: 8763515
Drug: Alteplase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (100 mg over 3 hours)
Study: 1663571
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens (Premarin)
Study: 1663571
Drug: Micronized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized oral progesterone
Study: 7027873
Drug: Oral bromhexine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromhexine, 32 mg/day
Study: 24452943
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment with optimal mineral-content diet (diet group, 27 subjects)